↓ Skip to main content

Dove Medical Press

Article Metrics

Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms

Overview of attention for article published in Drug Design, Development and Therapy, September 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
32 Mendeley
Title
Bulgecin A as a &beta;-lactam enhancer for carbapenem-resistant<em> Pseudomonas aeruginosa</em> and carbapenem-resistant <em>Acinetobacter baumannii</em> clinical isolates containing various resistance mechanisms
Published in
Drug Design, Development and Therapy, September 2016
DOI 10.2147/dddt.s110193
Pubmed ID
Authors

Skalweit, Mei Li

Abstract

Genetic screening of Pseudomonas aeruginosa (PSDA) and Acinetobacter baumannii (ACB) reveals genes that confer increased susceptibility to β-lactams when disrupted, suggesting novel drug targets. One such target is lytic transglycosylase. Bulgecin A (BlgA) is a natural product of Pseudomonas mesoacidophila and a lytic transglycosolase inhibitor that works synergistically with β-lactams targeting PBP3 for Enterobacteriaceae. BlgA also weakly inhibits di-Zn(2+) metallo-β-lactamases like L1 of Stenotrophomonas maltophilia. We hypothesized that because of its unique mechanism of action, BlgA could restore susceptibility to carbapenems in carbapenem-resistant PSDA (CR-PSDA) and carbapenem-resistant ACB, as well as ACB resistant to sulbactam. A BlgA-containing extract was prepared using a previously published protocol. CR-PSDA clinical isolates demonstrating a variety of carbapenem resistance mechanisms (VIM-2 carbapenemases, efflux mechanisms, and AmpC producer expression) were characterized with agar dilution minimum inhibitory concentration (MIC) testing and polymerase chain reaction. Growth curves using these strains were prepared using meropenem, BlgA extract, and meropenem plus BlgA extract. A concentrated Blg A extract combined with low concentrations of meropenem, was able to inhibit the growth of clinical strains of CR-PSDA for strains that had meropenem MICs ≥8 mg/L by agar dilution, and a clinical strain of an OXA-24 producing ACB that had a meropenem MIC >32 mg/L and intermediate ampicillin/sulbactam susceptibility. Similar experiments were conducted on a TEM-1 producing ACB strain resistant to sulbactam. BlgA with ampicillin/sulbactam inhibited the growth of this organism. As in Enterobacteriaceae, BlgA appears to restore the efficacy of meropenem in suppressing the growth of CR-PSDA and carbapenem-resistant ACB strains with a variety of common carbapenem resistance mechanisms. BlgA extract also inhibits VIM-2 β-lactamase in vitro. BlgA may prove to be an exciting adjunctive compound to extend the life of carbapenems against these vexing pathogens.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 19%
Student > Ph. D. Student 5 16%
Student > Bachelor 4 13%
Student > Postgraduate 3 9%
Unspecified 2 6%
Other 5 16%
Unknown 7 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 22%
Agricultural and Biological Sciences 5 16%
Chemistry 4 13%
Immunology and Microbiology 3 9%
Unspecified 2 6%
Other 4 13%
Unknown 7 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2016.
All research outputs
#3,699,124
of 8,497,409 outputs
Outputs from Drug Design, Development and Therapy
#226
of 1,067 outputs
Outputs of similar age
#106,132
of 254,508 outputs
Outputs of similar age from Drug Design, Development and Therapy
#10
of 62 outputs
Altmetric has tracked 8,497,409 research outputs across all sources so far. This one has received more attention than most of these and is in the 55th percentile.
So far Altmetric has tracked 1,067 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,508 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.